Tango Therapeutics TNGX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's stock-based comp?
- Tango Therapeutics (TNGX) reported stock-based comp of $10.8M in Q1 2026.
- How has Tango Therapeutics's stock-based comp changed year-over-year?
- Tango Therapeutics's stock-based comp increased by 48.8% year-over-year, from $7.26M to $10.8M.
- What is the long-term trend for Tango Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Tango Therapeutics's stock-based comp has grown at a 35.5% compound annual growth rate (CAGR), from $7.83M to $26.43M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.